Division of General Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA.
J Thromb Thrombolysis. 2021 Jul;52(1):331-337. doi: 10.1007/s11239-020-02294-2. Epub 2020 Oct 2.
Low-dose unfractionated heparin (LDUH) prophylaxis decreases the incidence of venous thromboembolism (VTE) in hospitalized patients, but increases the risk of bleeding events. Patients who develop a prolonged activated partial thromboplastin time (aPTT) while on LDUH may be at higher risk for bleeding complications. To determine the incidence and risk factors for aPTT prolongation in hospitalized patients receiving LDUH thromboprophylaxis, we performed a retrospective pharmacoepidemiologic cohort study of adult patients admitted to an academic medical center from September 2013 through September 2015. Among 3857 patients with at least one aPTT checked within 24 h of LDUH administration, aPTT prolongation > 1.5 times the upper limit of normal occurred in 131 (3.4%). Age 68-78 years (OR 1.6, 95% CI 1.01-2.4), age > 78 years (OR 1.9, 95% CI 1.3-2.9), female gender (OR 1.9, 95% CI 1.4-2.5), black race (OR 1.6, 95% CI 1.1-2.3), low BMI (OR 1.8, 95% CI 1.3-2.5), being admitted to a surgical service (OR 0.5, 95% CI 0.3-0.8), and receipt of high-dose (> 10,000 units in a day) unfractionated heparin prophylaxis (OR 1.4, 95% CI 1.003-2.0), were independently associated with aPTT prolongation after LDUH exposure. LDUH VTE prophylaxis is associated with aPTT prolongation in 3.4% of general hospitalized patients. We demonstrated several factors independently associated with aPTT prolongation. Monitoring aPTT levels may be indicated for select patients on LDUH thromboprophylaxis who are at high risk or consequence of bleeding and for aPTT prolongation.
低剂量未分级肝素(LDUH)预防可降低住院患者静脉血栓栓塞(VTE)的发生率,但会增加出血事件的风险。接受 LDUH 血栓预防治疗的患者,其活化部分凝血活酶时间(aPTT)延长可能会增加出血并发症的风险。为了确定接受 LDUH 预防性抗凝治疗的住院患者发生 aPTT 延长的发生率和危险因素,我们对 2013 年 9 月至 2015 年 9 月期间在学术医疗中心住院的成年患者进行了回顾性药物流行病学队列研究。在 3857 例至少有一次在接受 LDUH 治疗后 24 小时内检查 aPTT 的患者中,有 131 例(3.4%)的 aPTT 延长超过正常上限的 1.5 倍。68-78 岁年龄组(比值比 1.6,95%可信区间 1.01-2.4)、年龄>78 岁(比值比 1.9,95%可信区间 1.3-2.9)、女性(比值比 1.9,95%可信区间 1.4-2.5)、黑种人(比值比 1.6,95%可信区间 1.1-2.3)、低体重指数(比值比 1.8,95%可信区间 1.3-2.5)、被收入外科病房(比值比 0.5,95%可信区间 0.3-0.8)和接受高剂量(每天>10000 单位)未分级肝素预防(比值比 1.4,95%可信区间 1.003-2.0),与 LDUH 暴露后 aPTT 延长独立相关。LDUH VTE 预防在 3.4%的普通住院患者中导致 aPTT 延长。我们发现几个因素与 aPTT 延长独立相关。对于接受 LDUH 血栓预防治疗且出血风险高或后果严重的患者,以及 aPTT 延长的患者,监测 aPTT 水平可能是必要的。